CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Ravgen specializing in non-invasive prenatal genetic testing and paternity testing, Ravgen is focused on developing non-invasive prenatal diagnostic tests based on fetal DNA present in maternal blood. Diagnose single gene disorders, such as cystic fibrosis, sickle cell anemia and Downs syndrome, establish paternity and more early on in pregnancy.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Axis Shield PoC AS, a subsidiary of Abbott Laboratories, is a Norwegian company located in Oslo that manufactures diagnostic testing devices. Kjersti Grimsrud has been the CEO since 1987.

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative compounds and services based on its proprietary gene regulating and DNA production technologies. CytoGenix has products in pre-clinical development including an antimicrobial compound, DNA vaccines and anti-herpes and anti-inflammatory topical creams. The Company has developed a cell free process for synthesizing DNA which it uses for its own products as well as marketing specific compounds to other companies. CytoGenix, Inc. currently has 11 granted patents (1 US, 1 China, 9 Europe) covering our basic ssDNA expression technology, with one additional allowance (India) pending. We have an additional 11 applications pending in various countries which are currently progressing through the normal prosecution process. The Company actively collaborates with numerous academic centers of excellence, government agencies and biotechnology industry partners. Cytogenix, Inc. is publicly traded under the symbol CYGX on the NASDAQ Over the Counter Bulletin Board.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California in 1971, but conducted most of its operations in nearby Emeryville. Before merging with another company in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

PBL develops innovative technologies from public and private sources worldwide - turning ideas into patented, scientifically validated and licensable technologies. PBL invests in building intellectual property protection, and develops technologies through proof-of-concept and prototype stage and licenses onwards to a wide variety of industry sectors. Our interests cover AgBiotech, Food / Nutrition, Microbiology, Biotechnology and related Life Science industries. We market our technologies internationally and have regular contact with a very wide range of industrial customers, licensees and development partners.

EarlyDiagnostics, Inc. is an American company located in Los Angeles, CA. The firm develops cloud-based platform for integrative bioinformatics analysis. It was founded in 2017 by Wing H. Wong, Wenyuan Li and Xianghong Jasmine Zhou. Xianghong Jasmine Zhou has been the CEO since the company founding.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Fuso Pharmaceutical Industries, Ltd. engages in the manufacture and sale of ethical pharmaceutical and medical equipment. It operates through the Pharmaceuticals and Real Estate divisions. The Pharmaceuticals division deals with the manufacture and sale of pharmaceutical products which mainly focus on prescription drugs, infusions, and artificial kidney dialysis solutions. The Real Estate division handles leasing of real estate properties. The company was founded on March 25, 1937 and is headquartered in Osaka, Japan.

KeyGene NV provides its partners and customers in the plant breeding industry contract research, partnerships and molecular genetic services. It delivers novel enabling technologies and applications to support companies and institutes that carry out fundamental or applied genetic genomic research and that seek to enhance the quality of their products through the improvement of their genetic material. The company was established in 1989 and is headquartered in Wageningen, the Netherlands.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

The company is part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has over 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings.\nFinnzymes, founded in 1986, is a leader in the development of PCR, quantitative real-time PCR, transposon and RNA technologies. Its aim is to develop products which make the difference, products that deliver results not achievable otherwise.

Genetic Technologies is a global molecular diagnostic business with an extensive range of international patents and a portfolio of tests and related services. Our aim is simple: to concentrate on markets where we can establish a long-term dominant position by providing tests that genuinely affect clinical outcomes. We are already the leading non-government genetic testing business in Australia, and through our wholly owned subsidiary Phenogen Sciences, we now have a solid and growing presence in the USA. We remain committed to the development of a global portfolio of cancer management tests. The first of which is the Breast Cancer Risk Assessment Test, BREVAGenTM.